That raises the prospect, she said, that patients will stop taking the drugs and regain weight, which will lead to poor clinical outcomes. Join our commenting forum Join thought-provoking conversations, follow other Independent readers and see their replies Comments
Ellerby LM, Ellerby HM, Park SM, Holleran AL, Murphy AN, Fiskum G et al
Because I am always about how do we intervene with the things that [00:43:00] you don't require from me
The FDA has been vocal about its concerns in this category
In animal studies, BPC-157 supports new blood vessel growth, helps cells migrate into injury sites, and balances inflammation
those who used sodium-glucose cotransporter-2, or SGLT2, inhibitors (n = 258,614)